• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment.

作者信息

Gazzaniga Paola, Raimondi Cristina, Urbano Federica, Cortesi Enrico

机构信息

All authors: Sapienza University of Rome, Rome, Italy.

出版信息

JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.17.00277.

DOI:10.1200/PO.17.00277
PMID:35135115
Abstract
摘要

相似文献

1
EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment.表皮生长因子受体抑制剂作为一名转移性结直肠癌突变患者的二线治疗：利用循环肿瘤DNA实现个性化治疗
JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.17.00277.
2
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.通过甲基化和突变特征评估转移性结直肠癌患者循环肿瘤DNA中从RAS突变型到RAS野生型的真正转变。
Cancer Lett. 2021 Jun 1;507:89-96. doi: 10.1016/j.canlet.2021.03.014. Epub 2021 Mar 18.
3
Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.转移性结直肠癌患者的游离 DNA 中出现的 RAS、BRAF 和 EGFR 突变与一线抗 EGFR 治疗的原发性和继发性耐药均相关。
Int J Clin Oncol. 2020 Aug;25(8):1523-1532. doi: 10.1007/s10147-020-01691-0. Epub 2020 May 11.
4
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.循环肿瘤 DNA 突变等位基因分数对 RAS 突变转移性结直肠癌预后的影响。
Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.
5
Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.血浆 ctDNA RAS 状态可选择转移性结直肠癌患者进行抗 EGFR 治疗再挑战：一项荟萃分析。
Exp Oncol. 2021 Sep;43(3):252-256. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-3.16592.
6
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.RAS/PIK3CA/BRAF肿瘤突变作为转移性结直肠癌患者一线贝伐单抗化疗反应预测指标的回顾性研究。
BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6.
7
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.分析循环DNA和蛋白质生物标志物以预测瑞戈非尼的临床活性并评估转移性结直肠癌患者的预后：CORRECT试验的回顾性探索性分析
Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.
8
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.表皮生长因子受体（EGFR）基因拷贝数可预测RAS野生型及RAS/ BRAF/PIK3CA野生型转移性结直肠癌患者对抗表皮生长因子受体治疗的反应。
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
9
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.在组织检测 RAS 野生型的晚期结直肠癌患者中，游离 DNA 中的 RAS 和 BRAF 突变可预测西妥昔单抗单药治疗的疗效。
Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30.
10
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.基于西妥昔单抗的转移性结直肠癌患者中 RAS 突变的出现：一项研究方案。
BMC Cancer. 2019 Jun 28;19(1):640. doi: 10.1186/s12885-019-5826-7.

引用本文的文献

1
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions.探索结直肠癌液体活检领域：当前见解与未来方向
Int J Mol Sci. 2025 Aug 6;26(15):7619. doi: 10.3390/ijms26157619.
2
Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.转移性结直肠癌中循环肿瘤DNA从一线治疗到后续治疗的新RAS-WT演变
Cancers (Basel). 2025 Mar 22;17(7):1070. doi: 10.3390/cancers17071070.
3
Neo-RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review.
转移性结直肠癌中的新RAS野生型或RAS转化：一篇全面的叙述性综述。
Cancers (Basel). 2024 Nov 22;16(23):3923. doi: 10.3390/cancers16233923.
4
Kinetic Profiling of Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of Mutations in Neo--Wildtype Metastatic Colorectal Cancer Is Transient.在加拿大癌症临床试验组 CO.26 试验中，利用循环肿瘤 DNA 进行的突变动力学分析表明，新野生型转移性结直肠癌中突变的丢失是暂时的。
JCO Precis Oncol. 2024 Aug;8:e2400031. doi: 10.1200/PO.24.00031.
5
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.与 NeoRAS 野生型转移性结直肠癌相关的临床特征：SCRUM-Japan GOZILA 子研究。
Nat Commun. 2024 Jul 13;15(1):5885. doi: 10.1038/s41467-024-50026-4.
6
Anticancer drugs: How to select small molecule combinations?抗癌药物：如何选择小分子组合？
Trends Pharmacol Sci. 2024 Jun;45(6):503-519. doi: 10.1016/j.tips.2024.04.012. Epub 2024 May 22.
7
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.患者组织 RAS 野生型转移性结直肠癌无细胞 DNA 中连续 RAS 突变的评估：PERSEIDA（队列 2）研究。
Clin Transl Oncol. 2024 Oct;26(10):2640-2651. doi: 10.1007/s12094-024-03487-4. Epub 2024 Apr 20.
8
Emerging role of liquid biopsy in rat sarcoma virus mutated metastatic colorectal cancer: A case report.液体活检在大鼠肉瘤病毒突变转移性结直肠癌中的新作用：一例报告
World J Gastrointest Oncol. 2024 Jan 15;16(1):234-243. doi: 10.4251/wjgo.v16.i1.234.
9
Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.经多线治疗的转移性结直肠癌患者液体活检中 RAS 基因突变丢失。
Oncologist. 2024 Mar 4;29(3):e337-e344. doi: 10.1093/oncolo/oyad299.
10
Anti-epidermal growth factor receptor treatment for patients with Neo wild-type metastatic colorectal cancer: a case report of two cases.抗表皮生长因子受体治疗新野生型转移性结直肠癌患者：两例病例报告
Ther Adv Med Oncol. 2023 Nov 28;15:17588359231216090. doi: 10.1177/17588359231216090. eCollection 2023.